Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053144 · ClinicalTrials.gov registry record · Phase 1
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00053144: Completed Phase 1 study, sponsored by Roswell Park Cancer Institute.
NCT00053144 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00053144, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining irinotecan with cytarabine in treating patients who have refractory or recurrent acute myeloid leukemia or chronic myelogenous leukemia.
Interventions
- DRUG cytarabine
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-11 |
| Est. Completion | 2003-03 |
| Phase | Phase 1 |
What the finished NCT00053144 record still lists
NCT00053144 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which cytarabine is the first listed.
NCT00053144 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00053144 about?
NCT00053144 is a clinical study titled "Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining irinotecan with cytarabine in treating patients who have r...
What is the current status of trial NCT00053144?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-11. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00053144?
The interventions under investigation include: cytarabine (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00053144?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia